NEW YORK, NY / ACCESSWIRE / October 28, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Elite Pharmaceuticals Inc. (OTC: ELTP), NanoTech Entertainment, Inc. (OTC: NTEK), Medbox Inc. (OTC: MDBX) and Bioelectronics Corp. (OTC: BIEL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
To access our full PDF reports for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
ELTP Research Report: http://www.traders-choice.com/pdf?s=ELTP
NTEK Research Report: http://www.traders-choice.com/pdf?s=NTEK
MDBX Research Report: http://www.traders-choice.com/pdf?s=MDBX
BIEL Research Report: http://www.traders-choice.com/pdf?s=BIEL
============
Highlights from today's reports include:
On Tuesday, October 27, 2015, the U.S. markets finished weaker as NASDAQ ended at 5,030.15, down 0.09%, Dow Jones declined 0.24% to finish the day at 17,581.43, and the S&P closed at 2,065.89, down 0.26%.
- Following the broader market trend, shares of Elite Pharmaceuticals Inc. edged 3.43% higher to close Friday's session at USD 0.24, close to its 200-day moving average of USD 0.23. While oscillating between USD 0.24 and USD 0.26 during the session, the stocks recorded a trading volume of 1.10 million shares. The stock is trading at a P/E (TTM) multiple of 3.8 and at a price/sales multiple of 17.4. Recently on October 21, 2015, Elite Pharmaceuticals announced positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain. Meeting the primary endpoint (p = 0.001), the pivotal trial demonstrated statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Further, the trail's secondary endpoint results were consistent with primary findings and included safety measures. Following the results, the specialty pharmaceutical company intends to submit a New Drug Application to the U.S. Food and Drug Administration (USFDA) for abuse-deterrent ELI-200 by the end of 2015.
- Shares of NanoTech Entertainment, Inc. closed Friday's session at USD 0.0080, declining 20.00%. While oscillating in the range of USD 0.0071- USD 0.0095, the stock recorded a trading volume of 39.93 million shares, much above its three months average volume of 10.01 million shares. On October 23, 2015, NanoTech Entertainment announced that the company has entered into a licensing agreement with the San Francisco 49ers to start offering UltraFlix (the company's 4K video streaming channel) users Live 4K video coverage of the 49ers pre-game show and the 49ers TV video series, exclusively in 4K. While Harmonic, an UltraFlix partner, provides stunning quality, real-time 4K HEVC video encoding and adaptive streaming; another UltraFlix partner, Verizon Edgecast, manages the Live 4K ingest and reliable delivery to the growing line-up of 4K TV's sporting UltraFlix. Aaron Taylor, NanoTech's Executive Vice President of Sales & Marketing, commented, "We're honored to collaborate with two video delivery industry leaders to start our long-term Live 4K broadcast initiative. Our mission always has been, and continues to bee, the delivery of the most visually stunning movies, music, documentaries and award-winning television series...and now Live 4K!"
- Shares of Medbox Inc. edged 1.90% higher to close Friday's session at USD 0.107. While oscillating between USD 0.102 and USD 0.107, the stock recorded a trading volume of 0.76 million shares. On October 22, 2015, Medbox, Inc. announced that it has reached a settlement agreement with pending class action and derivative plaintiffs, who filed lawsuits against the company, its directors and executives, alleging misrepresentation of financial statements in fiscal 2012 and 2013. Medbox informed that though the settlement provides for the release and dismissal of all asserted claims, the same is contingent on final court approval in the derivative and class cases. Prior to this on October 20, 2015, Medbox announced the appointment of Jeff Goh, President and interim CEO, to the Company's Board of Directors. Ambassador Ned L. Siegel, Chairman of Medbox, said, "Jeff Goh's appointment as a director reflects the leadership he has demonstrated ushering in a new era for Medbox, and with his talented team, helping to position the company to pursue growth opportunities in the cannabis sector. We look forward to the positive influence and guidance he will provide as a member of our board."
- Shares of BioElectronics Corporation, the maker of advanced consumer pain management medical devices, ended flat on Friday to close the session at USD 0.001. A total of 81.5 million shares exchanged hands, which was below the stock’s 30-day average volume of 158.9 million shares. In a press release dated October 20, 2015, BioElectronics announced that it has received initial orders for its ActiPatch(R) Musculoskeletal Pain Relief products for 1,077 Lloyd's pharmacies, the second largest chain in the UK, and Gordons Chemist. Further, the Company informed that ActiPatch will be on promotion in Lloyd's stores and online beginning November 1, 2015. Commenting on the expansion of ActiPatch, Ben Fichter, Marketing Manager of BioElectronics, said, "The product placement and initial orders to stock these pharmacies are a substantial gain, but even more important long-term is the opportunity to work with the pharmacist to provide one-to-one consultation for chronic pain sufferers on the unique benefits and safety of ActiPatch. This is a great way to help patients discover how drug-free ActiPatch Therapy can help them manage their pain and restore daily activities while minimizing drug dependency."
--
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice